Delwedd Flaen

Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour

Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has expanded the scope of cancer treatment. Engineered MSCs expressing tumour necrosis factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) could serve as a platform for an efficient and targeted f...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Fakiruddin, Kamal Shaik, Ghazalli, Nadiah, Moon, Nian Lim, Zakaria, Zubaidah, Abdullah, Syahril
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: MDPI 2018
Mynediad Ar-lein:http://psasir.upm.edu.my/id/eprint/74939/1/ijms-19-02188.pdf
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
id oai:psasir.upm.edu.my:74939
record_format eprints
spelling oai:psasir.upm.edu.my:74939 http://psasir.upm.edu.my/id/eprint/74939/ Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour Fakiruddin, Kamal Shaik Ghazalli, Nadiah Moon, Nian Lim Zakaria, Zubaidah Abdullah, Syahril Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has expanded the scope of cancer treatment. Engineered MSCs expressing tumour necrosis factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) could serve as a platform for an efficient and targeted form of therapy. However, the presence of cancer stem cells (CSCs) that are resistant to TRAIL and apoptosis may represent a challenge for effective treatment. Nonetheless, with the discovery of small molecular inhibitors that could target CSCs and tumour signalling pathways, a higher efficacy of MSC-TRAIL mediated tumour inhibition can be achieved. This might pave the way for a more effective form of combined therapy, which leads to a better treatment outcome. In this review, we first discuss the tumour-homing capacity of MSCs, its effect in tumour tropism, the different approach behind genetically-engineered MSCs, and the efficacy and safety of each agent delivered by these MSCs. Then, we focus on how sensitisation of CSCs and tumours using small molecular inhibitors can increase the effect of these cells to either TRAIL or MSC-TRAIL mediated inhibition. In the conclusion, we address a few questions and safety concerns regarding the utilization of engineered MSCs for future treatment in patients. MDPI 2018 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/74939/1/ijms-19-02188.pdf Fakiruddin, Kamal Shaik and Ghazalli, Nadiah and Moon, Nian Lim and Zakaria, Zubaidah and Abdullah, Syahril (2018) Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour. International Journal of Molecular Sciences, 19. pp. 1-23. ISSN 1661-6596; ESSN: 1422-0067 10.3390/ijms19082188
institution UPM IR
collection UPM IR
language English
description Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has expanded the scope of cancer treatment. Engineered MSCs expressing tumour necrosis factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) could serve as a platform for an efficient and targeted form of therapy. However, the presence of cancer stem cells (CSCs) that are resistant to TRAIL and apoptosis may represent a challenge for effective treatment. Nonetheless, with the discovery of small molecular inhibitors that could target CSCs and tumour signalling pathways, a higher efficacy of MSC-TRAIL mediated tumour inhibition can be achieved. This might pave the way for a more effective form of combined therapy, which leads to a better treatment outcome. In this review, we first discuss the tumour-homing capacity of MSCs, its effect in tumour tropism, the different approach behind genetically-engineered MSCs, and the efficacy and safety of each agent delivered by these MSCs. Then, we focus on how sensitisation of CSCs and tumours using small molecular inhibitors can increase the effect of these cells to either TRAIL or MSC-TRAIL mediated inhibition. In the conclusion, we address a few questions and safety concerns regarding the utilization of engineered MSCs for future treatment in patients.
format Article
author Fakiruddin, Kamal Shaik
Ghazalli, Nadiah
Moon, Nian Lim
Zakaria, Zubaidah
Abdullah, Syahril
spellingShingle Fakiruddin, Kamal Shaik
Ghazalli, Nadiah
Moon, Nian Lim
Zakaria, Zubaidah
Abdullah, Syahril
Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour
author_facet Fakiruddin, Kamal Shaik
Ghazalli, Nadiah
Moon, Nian Lim
Zakaria, Zubaidah
Abdullah, Syahril
author_sort Fakiruddin, Kamal Shaik
title Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour
title_short Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour
title_full Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour
title_fullStr Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour
title_full_unstemmed Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour
title_sort mesenchymal stem cell expressing trail as targeted therapy against sensitised tumour
publisher MDPI
publishDate 2018
url http://psasir.upm.edu.my/id/eprint/74939/1/ijms-19-02188.pdf
_version_ 1819299198439260160
score 13.4562235

Eitemau Tebyg